Tillotts Pharma AG’s Acquisition Of The Rights To DIFICLIR™

Clifford Chance has advised Tillotts Pharma AG on the deal.

Tillotts Pharma AG agreed to acquire the rights to the drug DIFICLIRTM™ from Astellas Pharma Europe Ltd. for Europe, Middle East, Africa, Russia and selected CIS countries (Commonwealth of Independent States). The sale took the form of an asset deal.

Tillotts, part of the Japanese Zeria Group, is a fast-growing specialty pharma company. It is dedicated to the development, in/out-licensing and commercialisation of innovative pharmaceutical products for the digestive system. The new agreement allows Tillotts to provide a first-line treatment option to patients suffering from Clostridioides Difficile Infection (CDI), a serious and sometimes life threatening infection of the colon. DIFICLIR™ is a unique narrow-spectrum macrocyclic anti-bacterial agent available as film-coated tablets and granules. It is indicated for the treatment of CDI in adults and paediatric patients with a body weight of at least 12.5 kg. With the acquisition Tillotts plans to further expand in Europe in the near future.

The seller is part of the Astellas group, a pharmaceutical company with headquarters in Tokyo, conducting business in more than 70 countries. The transaction does not include the transfer of any of its employees or facilities.

The international Clifford Chance team comprised partner Christian Vogel (Picture), counsel Dominik Heß (both Corporate/M&A); partner Peter Dieners, counsel Claudia Nawroth and senior associate Sabrina Vivekens (all Corporate/Healthcare) as well as partner Marc Besen and counsel Dimitri Slobodenjuk (both Merger Control/Foreign Direct Investment, all Düsseldorf). The transaction was also advised by partner G. David Brinton (Corporate), counsel Daryl Fairbairn and associate Jennifer Saionz (both Corporate/IP, all New York) as well as partner Megan Gordon and counsel Catherine Ennis (both Litigation & Dispute Resolution, Washington, D.C.).

Involved fees earner: Marc Besen – Clifford Chance; David Brinton – Clifford Chance; Peter Dieners – Clifford Chance; Catherine Ennis – Clifford Chance; Daryl Fairbairn – Clifford Chance; Megan Gordon – Clifford Chance; Dominik Heß – Clifford Chance; Claudia Nawroth – Clifford Chance; Jennifer Saionz – Clifford Chance; Dimitri Slobodenjuk – Clifford Chance; Sabrina Vivekens – Clifford Chance; Christian Vogel – Clifford Chance;

Law Firms: Clifford Chance;

Clients: Tillotts Pharma AG ;